AMP-activated protein kinase alpha 1 (AMPKα1)

Overview

AMP-activated protein kinase alpha 1 (AMPKα1) is the catalytic alpha subunit encoded by the PRKAA1 gene and one of two alpha isoforms that form the catalytic core of AMP-activated protein kinase (AMPK), a heterotrimeric serine/threonine kinase composed of a catalytic alpha subunit together with regulatory beta and gamma subunits. The gamma subunit binds adenine nucleotides, so that a rising AMP:ATP ratio promotes phosphorylation of a conserved threonine in the alpha subunit activation loop by upstream kinases including LKB1 and CaMKK2. AMPKα1 thereby serves as the enzymatic output of the cell's principal energy sensor: when adenosine triphosphate levels fall, it phosphorylates substrates that switch on catabolic, ATP-generating processes such as fatty acid oxidation, glucose uptake, and mitochondrial biogenesis, while restraining ATP-consuming anabolic pathways including fatty acid and cholesterol synthesis via targets such as acetyl-CoA carboxylase and, indirectly, fatty acid synthase (FASN).

Downstream of activation, AMPKα1 inhibits mechanistic target of rapamycin (mTOR) signaling and directly phosphorylates ULK1, coupling energy stress to induction of autophagy and mitophagy; it also intersects with sirtuin 1 (SIRT1), PGC-1α–dependent mitochondrial biogenesis, Nrf2-mediated antioxidant defense, and the PI3K/AKT/mTOR axis that positions it opposite growth and proliferative signaling. These connections make AMPKα1 a recurring node in conditions defined by metabolic and oxidative stress, including type 2 diabetes and its complications such as diabetic neuropathy and nephropathy, obesity and impaired adipocyte catabolism, metabolic dysfunction–associated steatotic liver disease, cardiovascular disease encompassing myocardial fibrosis and heart failure with preserved ejection fraction, neurodegenerative disease such as Alzheimer's disease and Parkinson's disease, inflammation, aging, and cancer. Pharmacologically, AMPKα1 is the proximal effector of the biguanide metformin, whose actions on hepatic glucose output, and more speculatively on nociception and neuroprotection, are attributed largely to AMPK activation with downstream mTOR and MAPK suppression. It is likewise the convergence point for a broad set of natural products under investigation as metabolic modulators, including resveratrol, berberine, quercetin, kaempferol, urolithin A, and other polyphenols and flavonoids, as well as for pathway-directed agents such as the mTOR inhibitor sirolimus, and for signaling crosstalk with TGF-β, JAK2/STAT3, and PD-1/PD-L1 pathways in fibrotic and tumor settings.

Recent Publications Summary

Recent work positions AMPKα1 primarily as a therapeutic node rather than a study endpoint in itself, with the majority of reports characterizing compounds, formulas, or dietary interventions that engage AMPK and its downstream partners. A recurring axis is AMPK–mTOR coupling in autophagy and mitophagy. Urolithin A, a gut microbiome-derived mitophagy activator, activated AMPK while inhibiting mTOR in a two-hit (high-fat diet plus L-NAME) mouse model of heart failure with preserved ejection fraction, promoting ULK1-dependent autophagy initiation, restoring mitophagic flux and mitochondrial ultrastructure, and alleviating diastolic dysfunction, hypertrophy, and fibrosis, with concurrent modulation of a gut–ceramide axis 42432192Jul. resveratrol acted through the same general logic in an Aβ1-42-induced Alzheimer's disease model, where autophagy activation was linked to AMPK/ULK1 and SIRT1/NF-κB signaling alongside reduced aging markers and attenuated ROS production 42412302Jul. The converse configuration — mTOR activation with AMPK inhibition — was reported as a feature of impaired autophagic flux in diabetic neuropathy, where decreased LC3I/II ratio and p62 accumulation accompanied dysregulation of TFEB, FOXO3, and NRF2 and a proposed bidirectional loop between autophagy failure and lipid metabolic disturbance 42424320Jul. Several reviews frame AMPK in this same regulatory company: as a pathway whose dysregulation, together with mTOR, sustains a cycle of neuroinflammation and defective autophagy in neurodegeneration 41918200Apr; as one of the longevity pathways (with PI3K/AKT/mTOR and sirtuins) implicated in ovarian aging and targetable by AMPK activators, rapamycin, metformin, resveratrol, and melatonin 41833148Mar; as a target of polyphenols, flavonoids, alkaloids, terpenoids, and carotenoids that restore age-suppressed autophagic flux 41830033Mar; and as a fasting-responsive node, with AMPK and Sirtuin 1 activation proposed to mediate intermittent fasting's effects on autophagosome formation and brain aging 41811567Mar.

A second cluster addresses AMPK in cardiometabolic and hepatic disease, largely through traditional formulas and natural products evaluated with network pharmacology, molecular docking, and multi-omics. Guizhi Wuling Decoction reduced isoproterenol-induced myocardial fibrosis in C57BL/6J mice with improved mitochondrial ultrastructure, membrane potential, ATP production, and NAD+/NADH ratio, with integrated transcriptomic–proteomic analysis nominating AMPK/PGC-1α signaling and docking used to assess interactions of absorbed serum constituents 42462419Jul. Taohong Siwu decoction ameliorated hepatic lipid accumulation in female mice with HFpEF-associated fatty liver disease via an AMPK/SREBP1 mechanism 41951193Apr, and Jinshanxiaoke granules restored hepatic lipid homeostasis in high-fat-diet MASLD mice through Ampk/Ppar-α and Pi3k/Akt signaling 41990925Apr. In the kidney, Yitangkang decoction was studied by multi-omics as acting on glomerular filtration barrier damage in diabetic kidney disease through AMPKα1/ZDHHC8/SLC7A11/GPX4 and TGF-β/Smad pathways — one of the few reports naming the α1 isoform explicitly 41740333Feb. Persicaria lapathifolia leaf extract, profiled by GC-MS, LC-MS, HPTLC, and FTIR and tested in streptozotocin-diabetic rats against a metformin comparator, was validated in vitro through glucose uptake, GLUT4 translocation, and AMPK/Akt activation 41990533Apr, while cannabisin A and B from hemp seed hulls were reported to improve glucose homeostasis by selectively inhibiting PTP1B while stimulating AMPK, re-engaging insulin and leptin signaling 41831381Mar. Maternal broccoli powder intake during lactation upregulated AMPK phosphorylation in liver and hypothalamus of weaning female rats programmed by maternal protein restriction, alongside lower macrophage counts, NF-κB p65, and TNF-α 42036778Apr.

Mechanistic studies in adipose tissue and metabolic organs identify new components of AMPK circuitry. TBK1 was characterized as a nutrient- and inflammation-responsive brake on adipocyte AMPK: fasting or pharmacological AMPK activation induced Tbk1 transcription through a PGC1α/NRF1 axis that fed back to limit AMPK activity, an arrangement disrupted in obesity by chronically elevated basal TBK1; adipocyte-specific TBK1 deletion or amlexanox enhanced fasting-induced AMPK activation, mitochondrial function, and lipolytic gene expression, and combining amlexanox with the AMPK activator AICAR improved weight loss, glucose tolerance, and insulin sensitivity while suppressing inflammatory, lipogenic, and hepatic fibrotic programs 42100877May. Feimin was identified as an AMPK substrate linking energy sensing to transcription: on cold exposure AMPK phosphorylates Feimin, driving its nuclear translocation and direct interaction with PGC1α to induce thermogenic genes, with adipose-specific knockout abolishing cold-induced thermogenesis and worsening diet-induced obesity in a manner not rescued by a nuclear localization-defective mutant 42066046May. In diabetic nephropathy, GSTK1 was shown to limit renal ectopic fat deposition, with metformin — used as a pharmacological GSTK1 modulator — restoring GSTK1 expression in diabetic mice, relieving lipophagy dysfunction, and promoting CPT-1-mediated fatty acid β-oxidation 42069296May.

Oncology reports treat AMPK activity as both a therapeutic lever and a resistance mechanism. Sophoricoside inhibited Huh7 and HepG2 proliferation (IC50 ≈ 320 μM), reduced clonogenicity by roughly 65%, and suppressed migration and invasion by 60–70% with decreased PCNA, cyclin D1, and N-cadherin and increased E-cadherin, effects attributed to AMPK activation and supported by RNA-seq and Huh7 xenograft experiments 42003007Apr. Genome-wide CRISPR screening identified SLC5A11 as the mediator of metformin sensitivity underlying PD-L1 suppression, with metformin binding SLC5A11 at a pocket containing Asn78 and Glu102, activating AMPK, and downregulating JAK2-STAT1-IRF1; combining metformin with anti-PD1 produced synergistic antitumor effects and enhanced T cell infiltration in syngeneic lung and pancreatic models and increased PBMC-mediated cytotoxicity against tumor cells and patient-derived organoids 41690450Feb. In pancreatic ductal adenocarcinoma, temporal control of AMPK explained biphasic autophagy under irinotecan: DNA damage activated AMPK to induce early autophagy fueling fatty acid oxidation and ATP production, after which elevated ATP inactivated AMPK and activated mTOR, yet autophagy persisted via JNK1–Beclin-1, and FAO inhibition with KN510713 or FAO gene knockdown blocked autophagic flux and growth 42008004Apr. Beyond oncology, AMPK activation with downstream mTOR and MAPK inhibition is the proposed basis for metformin's analgesic effects, and a registered systematic review protocol has been published to evaluate randomized, double-blind trials of oral metformin for acute or chronic pain in adults 42468965Jul. berberine and metformin, both AMPK activators, were combined in streptozotocin-nicotinamide diabetic rats, where Chou-Talalay analysis of the novel object recognition discrimination index was used to quantify synergy, with mechanistic work centered on the AMPK-Nrf2 antioxidant axis and LC-MS/MS pharmacokinetic verification 42390621Jul.

What Changes, What Holds

1. AMPK-centered autophagy control is being used as a therapeutic handle across disease models
REINFORCES These studies mostly extend the established view that AMPKα1 couples energy stress to autophagy, mitophagy, and mTOR suppression. What changes is emphasis: AMPK is less often the endpoint and more often the pathway through which interventions are judged. The new work sharpens, rather than revises, the baseline model of AMPK as a central node linking metabolic stress to autophagic recovery 42432192Jul42412302Jul.

2. Natural products and formulas are increasingly being validated as AMPK-linked metabolic modulators
REINFORCES This paragraph strengthens the existing picture of AMPKα1 as a recurring target in diabetes, fatty liver disease, kidney injury, and cardiometabolic dysfunction. The main addition is not a new biology but a broader translational use case: complex mixtures and dietary interventions are being mapped onto AMPK, Akt, PPAR-α, and related pathways. That supports the baseline, while leaving mechanism-specific attribution and component causality unsettled 42462419Jul41740333Feb.

3. Adipose AMPK now appears to be under feedback control by a nutrient- and inflammation-responsive brake
NEW DIRECTION TBK1 adds a regulatory layer not covered in the Overview: AMPK is not only activated by upstream energy sensing, it is also restrained by a feedback circuit that can blunt fasting responses in obesity. That does not overturn AMPK’s established role, but it changes how its failure in obesity is understood. The evidence is strong preclinical work, yet whether this brake is a generalizable therapeutic target still needs confirmation 42100877May.

4. AMPK can function as both a tumor suppressive lever and a determinant of drug response
REINFORCES The oncology findings fit the baseline’s description of AMPKα1 as opposing growth and proliferative signaling through mTOR and related pathways. What is added is practical: AMPK activation is being used to explain antiproliferative effects and immunotherapy sensitization, while temporal AMPK control helps explain autophagy during chemotherapy. The pain-related metformin work also stays within the established pharmacology of AMPK-linked downstream inhibition 42003007Apr41690450Feb.

Overview update candidates: TBK1 as a feedback brake on adipocyte AMPK; Feimin as an AMPK substrate linking energy sensing to thermogenic transcription.